Cholinesterases, a Target of Pharmacology and Toxicology
Thursday, February 23, 2012
This review’s main focus is on cholinesterases as targets of toxins and drugs. The biochemistry of AChE and BuChE is also discussed. Drugs and toxins are divided in chapters according to target sites.
Estimation of drug-metabolizing capacity by CYP-genotyping and CYP-expression
Thursday, February 23, 2012
The lack of therapeutic effect of drugs or the appearance of undesired side-effects is partly caused by differences or changes in drug metabolism. This work aims to introduce an approach of combining CYP-genotyping and CYP-phenotyping tools to estimate patients’ drug-metabolizing capacity.
Gentronix Expands Specialist Sales Team in US and Europe
Friday, February 17, 2012
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Ferrer Announces Best-in-Class Results in Phase I for Lorediplon in Insomnia
Wednesday, February 15, 2012
Ferrer now seeking development partners for Lorediplon
that has demonstrated a highly promising efficacy, safety and tolerability profile.
The Hamner Institutes for Health Sciences and Alexandria Real Estate Equities, Inc. Announce Collaboration
Tuesday, February 14, 2012
The Research Triangle Park Collaboration Consortium is a new and highly unique hub that will bring together North Carolina's world-renowned universities, innovative public and private companies, and leading international institutions.
AiCuris Drug Letermovir Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus Prophylaxis
Tuesday, February 14, 2012
Trial shows a dose-dependent effect on the prevention of HCMV re-activation/re-infection and an excellent tolerability.
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
Monday, February 13, 2012
Company announces the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public.
Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease
Monday, February 13, 2012
The company presented preclinical studies of AT3375 as a monotherapy and in combination with enzyme replacement therapy for Gaucher disease during the 8th Annual Lysosomal Disease Network WORLD Symposium.
Nanoink Announces Launch of Contract Services Program for Live Single Cell Assay Work
Monday, February 13, 2012
Service offering expected to advance research programs involved with toxicity assessment, high content screening, and cell-cell communication.
|
|
|
| << | 1 2 3 4 5 6 7 | >> | | Showing Results 1 - 10 of 1994 |
|
|
